Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome

  • Christina Doesch
  • Björn Krämer
  • Tobias Geisler
  • Andreas E. May
  • Stefan-Martin Kroeber
  • Reinhard Kandolf
  • Meinrad Gawaz
Article

Abstract

Essential thrombocythemia (ET) is an acquired clonal hematological stem-cell disorder that is characterized by a persistent increase in platelet count over 600,000/μl and elevated megakaryocyte levels in the bone marrow. Patients with ET are on the one hand at risk of thrombosis and on the other hand of hemorrhagic events especially in patients with very high platelet accounts. We report two illustrative cases with ET and acute coronary syndrome from our recent clinical experience illustrating the challenges in the antithrombotic treatment of these patients.

Keywords

Essential thrombocythemia Thrombosis Acute coronary syndrome Cytoreductive treatment Antiplatelet therapy 

References

  1. 1.
    Tefferi A, Hoagland HC (1994) Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc 69(7):651–655PubMedGoogle Scholar
  2. 2.
    Daya SK, Gowda RM, Landis WA, Khan IA (2004) Essential thrombocythemia- related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology 55(3):319–323PubMedCrossRefGoogle Scholar
  3. 3.
    Koh KK, Cho SK, Kim SS, Oh BH, Lee YW (1993) Coronary vasospasm, multiple coronary thrombosis, unstable angina and essential thrombocytosis. Int J Cardiol 41(2):168–170PubMedCrossRefGoogle Scholar
  4. 4.
    Terada H, Satoh H, Uehara A (2000) Multivessel coronary thrombosis, acute myocardial infarction, and no reflow in a patient with essential thrombocythaemia. Heart 83(6):E10PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe T, Fujinaga H, Ikeda Y, Higashi T, Murakami M, Kawahara K, Hayashi I, Niki T, Shigekiyo T, Wakatsuki T (2005) Acute myocardial infarction in a patient with essential thrombocythemia who underwent successful stenting–a case report. Angiology 56(6):771–774PubMedCrossRefGoogle Scholar
  6. 6.
    Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292–2302PubMedCrossRefGoogle Scholar
  7. 7.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myelo-proliferative disorders. N Engl J Med 352(17):1779–1790PubMedCrossRefGoogle Scholar
  8. 8.
    Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275–290PubMedCrossRefGoogle Scholar
  9. 9.
    van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH (1996) The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 93(4):962–965PubMedCrossRefGoogle Scholar
  10. 10.
    Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A (1998) Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 244(1):49–53PubMedCrossRefGoogle Scholar
  11. 11.
    Petrides PE, Siegel F (2006) Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis 36(3):379–384PubMedCrossRefGoogle Scholar
  12. 12.
    Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8(3):556–562PubMedGoogle Scholar
  13. 13.
    Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27(20):2420–2425PubMedCrossRefGoogle Scholar
  14. 14.
    Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, Herdeg C, May AE, Gawaz M (2007) Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30(2):372–374PubMedCrossRefGoogle Scholar
  15. 15.
    Gawaz M, Ruf A, Neumann FJ, Pogatsa-Murray G, Dickfeld T, Zohlnhofer D, Schomig A (1998) Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 80(6):994–1001PubMedGoogle Scholar
  16. 16.
    Landolfi R, Di Gennaro L, Novarese L, Patrono C (2006) Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost 32(3):251–259PubMedCrossRefGoogle Scholar
  17. 17.
    Tefferi A (2006) Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 13(2):93–98PubMedCrossRefGoogle Scholar
  18. 18.
    Harrison CN, Campbell PJ, Buck G Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) United Kingdom medical research council primary thrombocythemia 1 study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Christina Doesch
    • 1
  • Björn Krämer
    • 1
  • Tobias Geisler
    • 1
  • Andreas E. May
    • 1
  • Stefan-Martin Kroeber
    • 2
  • Reinhard Kandolf
    • 3
  • Meinrad Gawaz
    • 1
  1. 1.Department of Cardiology and Cardiovascular DiseaseTuebingenGermany
  2. 2.Institute of Pathology KoblenzKoblenzGermany
  3. 3.Institute of Molecular PathologyTuebingenGermany

Personalised recommendations